Literature DB >> 19775500

Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.

Paolo Fusar-Poli1, Paul Allen, Sagnik Bhattacharyya, José A Crippa, Andrea Mechelli, Stefan Borgwardt, Rocio Martin-Santos, Marc L Seal, Colin O'Carrol, Zerrin Atakan, Antonio W Zuardi, Philip McGuire.   

Abstract

Cannabis sativa, the most widely used illicit drug, has profound effects on levels of anxiety in animals and humans. Although recent studies have helped provide a better understanding of the neurofunctional correlates of these effects, indicating the involvement of the amygdala and cingulate cortex, their reciprocal influence is still mostly unknown. In this study dynamic causal modelling (DCM) and Bayesian model selection (BMS) were used to explore the effects of pure compounds of C. sativa [600 mg of cannabidiol (CBD) and 10 mg Delta 9-tetrahydrocannabinol (Delta 9-THC)] on prefrontal-subcortical effective connectivity in 15 healthy subjects who underwent a double-blind randomized, placebo-controlled fMRI paradigm while viewing faces which elicited different levels of anxiety. In the placebo condition, BMS identified a model with driving inputs entering via the anterior cingulate and forward intrinsic connectivity between the amygdala and the anterior cingulate as the best fit. CBD but not Delta 9-THC disrupted forward connectivity between these regions during the neural response to fearful faces. This is the first study to show that the disruption of prefrontal-subocritical connectivity by CBD may represent neurophysiological correlates of its anxiolytic properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19775500     DOI: 10.1017/S1461145709990617

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  58 in total

1.  Cannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect.

Authors:  Christine A Rabinak; Chandra Sekhar Sripada; Mike Angstadt; Harriet de Wit; K Luan Phan
Journal:  J Neural Transm (Vienna)       Date:  2011-12-11       Impact factor: 3.575

Review 2.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

3.  A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.

Authors:  Khalid A Jadoon; Garry D Tan; Saoirse E O'Sullivan
Journal:  JCI Insight       Date:  2017-06-15

Review 4.  Anatomical insights into the interaction of emotion and cognition in the prefrontal cortex.

Authors:  Rebecca D Ray; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2011-08-25       Impact factor: 8.989

Review 5.  Pharmacological treatment of anxiety disorders: current treatments and future directions.

Authors:  Frank J Farach; Larry D Pruitt; Janie J Jun; Alissa B Jerud; Lori A Zoellner; Peter P Roy-Byrne
Journal:  J Anxiety Disord       Date:  2012-08-15

Review 6.  Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

Authors:  Ethan B Russo
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 7.  Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Authors:  Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

Review 8.  Spicing things up: synthetic cannabinoids.

Authors:  Max Spaderna; Peter H Addy; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

Review 9.  Cannabinoids in experimental stroke: a systematic review and meta-analysis.

Authors:  Timothy J England; William H Hind; Nadiah A Rasid; Saoirse E O'Sullivan
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

Review 10.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.